A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
Recruiting now · Early Phase 1
Conditions studied: Non-Hodgkin Lymphoma, B-cell
In brief
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous chimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
Key facts
- Study ID
- NCT06446128
- Run by
- Shanghai Cell Therapy Group Co.,Ltd
- People needed
- 20
- Starts
- 2024-05-07
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2025-08-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mengchao Cancer Hospital — Shanghai, Shanghai Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.